View in EDS HTML Full Text PDF Full Text

PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.

Saved in:
Bibliographic Details
Title: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.
Authors: Wei J; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA., Wang J; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA. jing_wang1@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. jing_wang1@dfci.harvard.edu., Guan W; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA., Li J; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.; Engineering Research Center of Cell & Therapeutic Antibody, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China., Pu T; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA., Corey E; Department of Urology, University of Washington, Seattle, WA, 98195, USA., Lin TP; Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, 11217, Republic of China.; Department of Urology, School of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, 11221, Republic of China., Gao AC; Department of Urologic Surgery, University of California, Davis, Sacramento, CA, 95817, USA., Wu BJ; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA. boyang.wu@wsu.edu.
Source: EMBO molecular medicine [EMBO Mol Med] 2025 Feb; Vol. 17 (2), pp. 336-364. Date of Electronic Publication: 2025 Jan 02.
Publication Type: Journal Article
Journal Info: Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39748059
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wei+J%22">Wei J</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA. jing_wang1@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. jing_wang1@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Guan+W%22">Guan W</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.; Engineering Research Center of Cell & Therapeutic Antibody, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.<br /><searchLink fieldCode="AU" term="%22Pu+T%22">Pu T</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.<br /><searchLink fieldCode="AU" term="%22Corey+E%22">Corey E</searchLink>; Department of Urology, University of Washington, Seattle, WA, 98195, USA.<br /><searchLink fieldCode="AU" term="%22Lin+TP%22">Lin TP</searchLink>; Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan, 11217, Republic of China.; Department of Urology, School of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan, 11221, Republic of China.<br /><searchLink fieldCode="AU" term="%22Gao+AC%22">Gao AC</searchLink>; Department of Urologic Surgery, University of California, Davis, Sacramento, CA, 95817, USA.<br /><searchLink fieldCode="AU" term="%22Wu+BJ%22">Wu BJ</searchLink>; Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA. boyang.wu@wsu.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101487380%22">EMBO molecular medicine</searchLink> [EMBO Mol Med] 2025 Feb; Vol. 17 (2), pp. 336-364. <i>Date of Electronic Publication: </i>2025 Jan 02.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22EMBO+Press%22">EMBO Press </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>101487380 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1757-4684 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217574676%22">17574676 </searchLink><i>NLM ISO Abbreviation: </i>EMBO Mol Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39748059
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s44321-024-00186-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 336
    Titles:
      – TitleFull: PlexinD1 is a driver and a therapeutic target in advanced prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wei J
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Guan W
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Pu T
      – PersonEntity:
          Name:
            NameFull: Corey E
      – PersonEntity:
          Name:
            NameFull: Lin TP
      – PersonEntity:
          Name:
            NameFull: Gao AC
      – PersonEntity:
          Name:
            NameFull: Wu BJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2025 Feb
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1757-4684
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: EMBO molecular medicine
              Type: main
ResultId 1